Immediate Impact

1 by Nobel laureates 1 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
2023 Standout
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
2022 Standout
6 intermediate papers

Works of D. Paillotin being referenced

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
2011
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1
2001
and 1 more

Author Peers

Author Last Decade Papers Cites
D. Paillotin 487 478 85 99 24 578
Emily S. Lebow 358 357 40 100 33 553
C. Grafton 231 346 216 30 18 518
J.A. Bogart 506 362 104 170 18 592
Noelia Vilariño 303 396 33 60 27 559
D C Ihde 242 455 261 35 18 595
Haruhito Kamei 456 383 52 21 35 563
Alessandro Bertolini 516 504 23 57 22 736
Ebenezer A. Kio 262 343 37 82 27 692
Jun Sugisaka 281 587 50 50 20 662
Sachiko Kawana 242 492 53 47 17 576

All Works

Loading papers...

Rankless by CCL
2026